GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
3.060
+0.050 (1.66%)
Nov 22, 2024, 4:00 PM EST - Market closed
GT Biopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 22, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 7 | 11 | 29 | 93 | 36 | 5 | |
| Market Cap Growth | -47.35% | -63.37% | -69.01% | 159.67% | 556.05% | -83.27% | |
| Enterprise Value | 0 | -5 | 8 | 57 | 58 | 18 | |
| Last Close Price | 3.06 | 7.65 | 26.57 | 91.50 | 216.24 | 41.31 | |
| PB Ratio | 3.26 | 1.41 | 2.46 | 4.25 | -1.22 | -0.28 | |
| P/TBV Ratio | 2.46 | 1.41 | 2.46 | 4.25 | - | - | |
| Debt / Equity Ratio | - | 0.01 | 0.01 | 0.00 | -0.89 | -0.69 | |
| Quick Ratio | 1.38 | 2.11 | 3.34 | 3.12 | 0.15 | 0.00 | |
| Current Ratio | 1.45 | 2.12 | 3.35 | 3.14 | 0.16 | 0.01 | |
| Return on Equity (ROE) | -204.08% | -79.09% | -124.15% | - | - | - | |
| Return on Assets (ROA) | -75.14% | -55.02% | -54.33% | -190.04% | -139.59% | -55.52% | |
| Return on Capital (ROIC) | -141.15% | -87.29% | -78.50% | -381.56% | - | -88.28% | |
| Earnings Yield | -180.62% | -71.93% | -72.42% | -62.35% | -78.97% | -707.56% | |
| FCF Yield | -182.58% | -83.81% | -52.77% | -16.77% | -20.27% | -66.99% | |
| Buyback Yield / Dilution | -31.99% | -26.87% | -13.19% | -542.06% | -29.59% | -14.50% | |
| Total Shareholder Return | -31.99% | -26.87% | -13.19% | -542.06% | -29.59% | -14.50% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.